BioLife Solutions' cell and tissue storage/shipping medium HypoThermosol will be used in ongoing clinical studies of Intercytex's cell-based treatment ICX-RHY-013 in patients with burn injuries and recessive dystrophic epidermolysis bullosa in the U.S. and Europe. HypoThermosol will be used as the delivery solution for therapeutic cells and as the placebo in the control group.

Related Summaries